Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ).
Lepu Biopharma Co., Ltd. has announced amendments to its Articles of Association following the issuance of new H Shares, as approved by the China Securities Regulatory Commission. This move, which increases the company’s registered capital, is part of a broader strategy to enhance its capital structure and strengthen its market positioning.
The most recent analyst rating on (HK:2157) stock is a Sell with a HK$5.00 price target. To see the full list of analyst forecasts on Lepu Biopharma Co. Ltd. Class H stock, see the HK:2157 Stock Forecast page.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biopharmaceutical industry. The company is involved in the issuance of H Shares on the Hong Kong Stock Exchange, reflecting its focus on expanding its capital structure and market presence.
Average Trading Volume: 14,480,977
Technical Sentiment Signal: Hold
Current Market Cap: HK$10.72B
See more data about 2157 stock on TipRanks’ Stock Analysis page.